TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$250 Million

Neurocrine Biosciences

Follow-on Offering

Co-Manager, February 2015

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.